Cancer patients within the top group (25% highest SOX2 expression; log2 counts > 10.06) have a significantly (P = 1.27 × 10−23, log-rank test) lower overall probability of survival compared with cancer patients within the bottom group (25% lowest SOX2 expression; log2 counts < 1.68) (Supplementary Figure S1B; Supplementary Table S14). This evidence concerns the gene SOX2 and cancer.